The last of Novo Nordisk AS's 10 PIONEER clinical development program trials - PIONEER 6 - has read out early with good results, allowing the Danish diabetes fighter to file its oral GLP-1 semaglutide in the first-half of the new year, earlier than previously expected, chief science officer Mads Krogsgaard Thomsen told Scrip.
Thomsen, who has been with the Danish group for more than 25 years, also said Novo Nordisk may use a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)